2174264_eisai_logo-web

Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016
Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …

doc_writing

One in three antibiotic prescriptions in US unnecessary, says CDC

May 5, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary

Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …

headquarters_3_web

Eli Lilly’s cancer drug candidate scores FDA priority review

May 5, 2016
Eli Lilly, US FDA, oncology, regulation

US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …

Biogen to spin off its haemophilia business

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

Nice extends price-negotiation talks for PTC’ muscle wasting drug

May 4, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation

UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …

Pfizer revenue jumps 20%; ups FY16 outlook

May 4, 2016
Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales

US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …

Sun Pharma to partner with ICGEB to develop novel Dengue treatment

May 4, 2016
Research and Development Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical

Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to …

US biotech company to try resurrect the clinically dead

May 4, 2016
Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect

A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …

Pfizer joins the race, bids for Medivation – Reports

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …

amgen_flag

FDA grants priority review for Amgen leukaemia drug

May 4, 2016
Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric

Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …

ims_health_quintiles

Quintiles to merge with IMS Health

May 3, 2016
Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger

IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …

parks

New CFO at Mylan

May 3, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks

Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …

google

Google files for US patent to electronic eye lens

May 3, 2016
Manufacturing and Production, Research and Development Alphabet, google, lens, patent, research

Alphabet Inc (Nasdaq: GOOG) has filed a patent application for a device that can be implanted in the eye to …

biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

May 3, 2016
Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …

vaccination

In-depth: MSF takes on Pfizer, GSK

May 3, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia

Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …

France to push for drug price control regulations at upcoming G7 summit

May 3, 2016
Manufacturing and Production Drug pricing, France, drug prices, g7 summit, hollande, irreversible, medicines, pharmaceutical, prices

France will urge its fellow G7 partners to introduce strict and final new limits to control the prices of new …

stocks1

Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…

May 3, 2016
Manufacturing and Production

Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …

regeneron

Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials

May 3, 2016
Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III

Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …

bill_ackman

Big investor hits back at critics as Valeant’s war of words gathers pace

May 3, 2016
Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …

The Gateway to Local Adoption Series

Latest content